Scientists reveal how miRNAs shape cancer and offer new paths for treatment

John­son & John­son and Pro­tag­o­nist Ther­a­peu­tics an­nounced two Phase 3 suc­cess­es for their oral IL-23 drug, show­cas­ing the first re­sults out of an ex­pan­sive piv­otal

CHICAGO — Use of conventional hormonal therapy for menopausal symptoms doubled the long-term risk of ovarian cancer and the risk of dying of the disease,

Last year, I sec­ond-guessed whether we should con­tin­ue run­ning an an­nu­al spe­cial re­port high­light­ing LGBTQ+ lead­ers in the bio­phar­ma in­dus­try. We al­ready had Women in